Goldman Sachs
STAB

Goldman Sachs’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Goldman Sachs’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-38
Closed -$1K – 6838
2013
Q3 		$1K Sell
38
-1,039
-96% -$34.4K ﹤0.01% 6537
2013
Q2 		$34K Buy
+1,077
New +$37.1K ﹤0.01% 6126

Other funds holding STAB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
PGCM
Prescott Group Capital Management Tulsa, Oklahoma $1B AUM 51.95% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $913M AUM 11.84% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs's STAB Position: Q4 2013 in Review

Goldman Sachs sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q4 2013, closing a stake of 38 shares — an estimated $1K sold.

Goldman Sachs first reported a position in STAB in Q2 2013 and held it in 2 quarters. The position peaked at $34K in Q2 2013. 39 funds tracked by Wall St. Rank hold STAB as of Q4 2013.

  • Goldman Sachs reported no remaining Statera Biopharma, Inc. Common Stock position as of Q4 2013 after selling out during the quarter.
  • Goldman Sachs sold 38 Statera Biopharma, Inc. Common Stock shares in Q4 2013, an estimated $1K.
  • Goldman Sachs first reported a position in Statera Biopharma, Inc. Common Stock in Q2 2013 and held it in 2 quarters.
  • Goldman Sachs's Statera Biopharma, Inc. Common Stock position peaked at $34K in Q2 2013.
  • 39 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q4 2013.

Based on Goldman Sachs's 13F filing for Q4 2013, filed 14 Feb 2014.